Brokerages expect Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to report earnings per share (EPS) of ($0.27) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Neoleukin Therapeutics’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.24). Neoleukin Therapeutics reported earnings per share of ($0.20) in the same quarter last year, which indicates a negative year-over-year growth rate of 35%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 11th.
On average, analysts expect that Neoleukin Therapeutics will report full-year earnings of ($1.09) per share for the current financial year, with EPS estimates ranging from ($1.17) to ($0.95). For the next fiscal year, analysts expect that the company will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.33) to ($1.02). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Neoleukin Therapeutics.
Neoleukin Therapeutics (NASDAQ:NLTX) last released its quarterly earnings results on Thursday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04).
Shares of NASDAQ:NLTX traded up $0.16 during midday trading on Thursday, hitting $10.14. 4,796 shares of the stock were exchanged, compared to its average volume of 218,631. The business’s 50-day simple moving average is $10.96. Neoleukin Therapeutics has a 12 month low of $9.38 and a 12 month high of $17.95. The firm has a market cap of $429.39 million, a PE ratio of -13.31 and a beta of 1.03.
In related news, SVP Carl Walkey sold 2,400 shares of the stock in a transaction on Wednesday, April 28th. The stock was sold at an average price of $12.58, for a total value of $30,192.00. Following the completion of the sale, the senior vice president now directly owns 1,357,162 shares of the company’s stock, valued at approximately $17,073,097.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jonathan G. Drachman purchased 40,000 shares of the stock in a transaction that occurred on Thursday, June 3rd. The stock was bought at an average cost of $9.48 per share, with a total value of $379,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,238,686 shares in the company, valued at approximately $21,222,743.28. The disclosure for this purchase can be found here. Insiders have sold 16,200 shares of company stock worth $190,476 over the last ninety days. 10.90% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Neoleukin Therapeutics by 0.9% in the 1st quarter. BlackRock Inc. now owns 2,709,825 shares of the company’s stock valued at $33,358,000 after buying an additional 24,915 shares during the last quarter. Point72 Asset Management L.P. raised its position in Neoleukin Therapeutics by 9.4% in the 1st quarter. Point72 Asset Management L.P. now owns 1,308,600 shares of the company’s stock valued at $16,109,000 after buying an additional 112,875 shares during the last quarter. Geode Capital Management LLC raised its position in Neoleukin Therapeutics by 13.0% in the 1st quarter. Geode Capital Management LLC now owns 537,242 shares of the company’s stock valued at $6,613,000 after buying an additional 61,936 shares during the last quarter. Morgan Stanley raised its position in Neoleukin Therapeutics by 123.8% in the 4th quarter. Morgan Stanley now owns 430,284 shares of the company’s stock valued at $6,067,000 after buying an additional 238,056 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Neoleukin Therapeutics by 1,091.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 338,530 shares of the company’s stock valued at $4,167,000 after buying an additional 310,107 shares during the last quarter. 65.51% of the stock is owned by institutional investors and hedge funds.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.